RT Journal Article
T1 Evaluation of the antioxidant activity of the marine pyrroloiminoquinone makaluvamines
A1 Alonso López, Eva
A1 Alvariño Romero, Rebeca
A1 Leirós Villalba, Marta
A1 Tabudravu, Jioji N.
A1 Feussner, Klaus
A1 Dam, Miriam A.
A1 Rateb, Mostafa E.
A1 Jaspars, Marcel
A1 Botana López, Luis Miguel
K1 Makaluvamine
K1 Zyzzya
K1 Oxidative stress
K1 Neurons
K1 Marine sponge
K1 nrf2
AB Makaluvamines are pyrroloiminoquinones isolated from Zyzzya sponges. Until now, they have been described as topoisomerase II inhibitors with cytotoxic effects in diverse tumor cell lines. In the present work, seven makaluvamines were tested in several antioxidant assays in primary cortical neurons and neuroblastoma cells. Among the alkaloids studied, makaluvamine J was the most active in all the assays. This compound was able to reduce the mitochondrial damage elicited by the well-known stressor H2O2. The antioxidant properties of makaluvamine J are related to an improvement of the endogenous antioxidant defenses of glutathione and catalase. SHSY5Y assays proved that this compound acts as a Nrf2 activator leading to an improvement of antioxidant defenses. A low concentration of 10 nM is able to reduce the reactive oxygen species release and maintain a correctmitochondrial function. Based on these results, non-substituted nitrogen in the pyrrole plus the presence of a p-hydroxystyryl without a double bond seems to be the most active structure with a complete antioxidant effect in neuronal cells.
PB MDPI
SN 1660-3397
YR 2016
FD 2016-10
LK http://hdl.handle.net/10347/15866
UL http://hdl.handle.net/10347/15866
LA eng
NO Alonso, E., Alvariño, R., Leirós, M., Tabudravu, J. N., Feussner, K., Dam, M. A., ... & Botana, L. M. (2016). Evaluation of the antioxidant activity of the marine pyrroloiminoquinone makaluvamines. Marine drugs, 14(11), 197.
NO The research leading to these results received funding from the following FEDER cofounded-grants. From CDTI and Technological Funds, supported by the Ministerio de Economía y Competitividad, AGL2012-40185-CO2-01, AGL2014-58210-R, and the Consellería de Cultura, Educación e Ordenación Universitaria, GRC2013-016, and through the Axencia Galega de Innovación, Spain, ITC-20133020 SINTOX. From CDTI under ISIP Programme, Spain, IDI-20130304 APTAFOOD. From the European Union’s Seventh Framework Programme managed by REA—Research Executive Agency (FP7/2007-2013) under grant agreement 312184 PHARMASEA.
DS Minerva
RD 23 abr 2026